Ownership and insider activity for Trevi Therapeutics, Inc. (TRVI): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis.
Price
| Price | $15.01 |
| Market Cap | $2.1B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-03 | Mathers Edward T | A-Award | 35,000 | $471K |
| 2026-06-03 | Colangelo Dominick | A-Award | 35,000 | $471K |
| 2026-06-03 | Meeker David P | A-Award | 35,000 | $471K |
| 2026-06-03 | VANLENT ANNE | A-Award | 35,000 | $471K |
| 2026-06-03 | Heffernan Michael Thomas | A-Award | 35,000 | $471K |
| 2026-02-19 | Cassella James V | A-Award | 215,000 | $2.3M |
| 2026-02-19 | Galletta Christopher | A-Award | 35,000 | $370K |
| 2026-02-19 | SCIASCIA THOMAS | A-Award | 85,000 | $898K |
| 2026-02-19 | GOOD JENNIFER L | A-Award | 675,000 | $7.1M |
| 2026-02-19 | Simon Farrell | A-Award | 160,000 | $1.7M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.3M | $22.0M | $17.2M | $57.3M | $45.0M | $36.8M | $12.6M | $32.4M | $34.1M | $18.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $107.9M | $50.6M | $73.5M | $169.3M |
| Receivables | $19000 | 0 | $184000 | $558000 | 0 | $241000 | 0 | 0 | $532000 | $986000 |
| Inventory | 0 | $63000 | $1.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $8.4M | $22.2M | $18.8M | $59.6M | $46.3M | $38.0M | $122.6M | $87.5M | $109.4M | $191.7M |
| Property, Plant & Equipment | $5000 | $14000 | $149000 | $430000 | $330000 | $184000 | $194000 | $1.6M | $1.2M | $855000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $8.4M | $22.2M | $20.5M | $60.0M | $47.1M | $38.5M | $123.0M | $89.4M | $110.9M | $193.4M |
| Accounts Payable | $445000 | $537000 | $603000 | $1.6M | $2.0M | $2.8M | $2.9M | $1.8M | $3.4M | $3.9M |
| Short-term Debt | $17.0M | $5.3M | 0 | 0 | 0 | $5.8M | $7.0M | 0 | 0 | 0 |
| Total Current Liabilities | $20.4M | $7.1M | $2.7M | $5.2M | $5.6M | $12.7M | $13.4M | $5.8M | $10.5M | $9.7M |
| Long-term Debt | $5.1M | 0 | $1.1M | 0 | $14.0M | $8.7M | $2.2M | 0 | 0 | 0 |
| Total Liabilities | $25.8M | $7.5M | $3.2M | $5.5M | $19.8M | $21.4M | $15.6M | $6.9M | $11.3M | $10.2M |
| Retained Earnings | -$72.2M | -$84.4M | -$109.5M | -$114.2M | -$147.0M | -$180.9M | -$210.1M | -$239.1M | -$287.0M | -$329.8M |
| Total Equity | -$17.4M | $14.8M | $17.3M | $54.5M | $27.3M | $17.1M | $107.5M | $82.5M | $99.6M | $183.2M |
| Total Debt | $22.1M | $5.3M | $1.1M | $356000 | $14.2M | $14.6M | $9.2M | $1.3M | $1.0M | $753000 |
| Net Debt | $13.8M | -$16.7M | -$16.1M | -$57.0M | -$30.8M | -$22.2M | -$111.3M | -$81.6M | -$106.6M | -$187.5M |
| Working Capital | -$12.0M | $15.0M | $16.1M | $54.4M | $40.7M | $25.2M | $109.2M | $81.7M | $98.9M | $181.9M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 37.28 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 104.82 |
Profitability
| Return on Equity | -23.59% |
| Return on Invested Capital | -18.46% |
| Return on Assets | -15.46% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARDX · NVAX · ORIC · PGEN · TERN · TRML · UPB
Explore sector: Healthcare · Biotechnology
More sections of TRVI: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks